{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-22-000047","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.978349+00:00","generated_at":"2026-06-24T02:57:16.260732+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss","bullets":["Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.","Operating loss $63.1M (vs $10.3M); net loss $64.5M (vs $11.1M); stock-based comp $36.3M.","FY2022 revenue guidance cut to $500-520M (2-6% growth) from prior expectations.","Headwinds: China lockdowns, European cold-chain logistics delays, execution issues, unfavorable FX.","Launched Fixed RNA Profiling Kit for FFPE; shipped Visium CytAssist; hired Jim Wilbur as CCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-22-000047","json":"https://secwatch.observer/filing/0001770787-22-000047.json","markdown":"https://secwatch.observer/filing/0001770787-22-000047.md","text":"https://secwatch.observer/filing/0001770787-22-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/0001770787-22-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000047/txg-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:57:16.260732+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}